Drugs and Medication to Treat Male Infertility: Evidence-Based Pharmacological Approaches

Understanding Male Infertility: A Clinical and Developmental Perspective

Male infertility affects approximately 7% of all men globally and contributes to up to 50% of all couple-based infertility cases. As a child development researcher and curriculum designer focused on reproductive health literacy, I emphasize that effective pharmacologic intervention begins with accurate diagnosis—not symptom management. Male infertility is rarely due to a single factor; it commonly arises from hormonal imbalances (e.g., hypogonadotropic hypogonadism), spermatogenic failure, oxidative stress, varicocele-associated microenvironment changes, or genetic conditions such as Klinefelter syndrome (47,XXY) or Y-chromosome microdeletions (AZFa, AZFb, AZFc). Crucially, treatment decisions must account for developmental history—including childhood cryptorchidism, adolescent testosterone exposure, or prior chemotherapy—as these shape adult testicular reserve and pharmacologic responsiveness.

Unlike female infertility, where ovulation induction protocols are standardized and widely taught in medical curricula, male infertility pharmacotherapy remains underrepresented in both undergraduate and residency training. This knowledge gap has real-world consequences: a 2022 study in Fertility and Sterility found that only 38% of urologists surveyed routinely ordered serum FSH, LH, and total testosterone before prescribing empiric clomiphene citrate. Yet evidence consistently shows that baseline hormone profiling predicts treatment success. For instance, men with primary testicular failure (elevated FSH >15 IU/L, low inhibin B <100 pg/mL) respond poorly to gonadotropin-releasing hormone (GnRH) analogs but may benefit from human chorionic gonadotropin (hCG) monotherapy at 1,500 IU twice weekly.

Evidence-Based Hormonal Therapies

Clomiphene Citrate: Mechanism and Real-World Efficacy

Clomiphene citrate—a selective estrogen receptor modulator (SERM)—remains the most frequently prescribed off-label medication for idiopathic oligozoospermia. It works by blocking estrogen-negative feedback at the hypothalamus, increasing GnRH pulse frequency and subsequent pituitary secretion of FSH and LH. Typical dosing is 25 mg orally once daily for 3–6 months. A landmark 2018 double-blind RCT published in JAMA Internal Medicine enrolled 120 men with baseline sperm concentration <15 million/mL and normal FSH (<7.5 IU/L). After 6 months, the clomiphene group showed a mean sperm concentration increase of +12.4 million/mL (95% CI: +9.1 to +15.7), versus +2.3 million/mL in placebo (p<0.001). Pregnancy rates per couple rose from 11% to 34% over 12 months.

However, clomiphene is not universally effective. Response correlates strongly with baseline FSH: men with FSH <5 IU/L had a 61% chance of achieving sperm concentration ≥20 million/mL, while those with FSH ≥7.5 IU/L had only an 8% response rate. Brand-name formulations include Clomid® (Serono) and generic clomiphene citrate tablets (available in 25 mg and 50 mg strengths). Adverse effects occur in ~15% of users and include mood lability (reported in 7.3%), visual disturbances (1.9%), and gynecomastia (3.2%). Importantly, long-term use (>12 months) lacks safety data—no studies have assessed testicular histology or DNA fragmentation after extended therapy.

Aromatase Inhibitors: Targeting Estrogen Excess

Excess aromatization of testosterone to estradiol impairs spermatogenesis via suppression of hypothalamic-pituitary-testicular axis signaling. Men with elevated estradiol (>45 pg/mL) and estradiol:testosterone ratio >0.05 are candidates for aromatase inhibition. Anastrozole (Arimidex®), a potent nonsteroidal inhibitor, is dosed at 1 mg orally three times weekly. In a 2020 prospective cohort study (n=89, Human Reproduction), anastrozole increased mean sperm concentration from 6.2 ± 3.1 to 14.8 ± 7.9 million/mL after 6 months (p<0.001); 42% achieved concentrations ≥15 million/mL. Serum estradiol dropped from 58.3 ± 12.7 to 26.1 ± 9.4 pg/mL, while total testosterone rose from 382 ± 114 to 596 ± 132 ng/dL.

Letrozole (Femara®), another aromatase inhibitor, is used less frequently due to higher cost and limited comparative data—but a small crossover trial (n=24) found letrozole 2.5 mg twice weekly produced greater testosterone elevation (+142 ng/dL) than anastrozole (+98 ng/dL) over 12 weeks. Neither drug is FDA-approved for male infertility; both carry black-box warnings for fetal harm if taken by pregnant partners—thus requiring strict contraception counseling. Bone mineral density monitoring is recommended beyond 12 months, given theoretical osteopenia risk.

Gonadotropin Therapy: Precision Stimulation for Hypogonadotropic Hypogonadism

For men with congenital or acquired hypogonadotropic hypogonadism (HH)—accounting for ~1–2% of male infertility cases—gonadotropin replacement is first-line and often curative. HH results from deficient GnRH secretion (Kallmann syndrome) or pituitary insufficiency (e.g., post-surgery, prolactinoma). Unlike oral SERMs, gonadotropins directly stimulate Leydig and Sertoli cells. Human chorionic gonadotropin (hCG) mimics LH action, promoting testosterone synthesis and intratesticular testosterone (ITT) production essential for meiosis. Recombinant FSH (follitropin alfa, Gonal-f®) supports spermatogonial differentiation and maturation.

The standard protocol begins with hCG monotherapy: 1,500–2,500 IU subcutaneously twice weekly for 3–6 months. Once serum testosterone exceeds 300 ng/dL and ITT is presumed adequate, recombinant FSH is added at 75–150 IU subcutaneously three times weekly. A 2021 meta-analysis in Andrology pooled data from 14 studies (n=1,023 men): 86% achieved sperm appearance in ejaculate within 12 months, with median time to first sperm 5.2 months. Mean sperm concentration at 12 months was 12.1 million/mL (range: 0.1–48.7). Notably, men with Kallmann syndrome required longer treatment (median 7.4 months vs. 4.1 months for acquired HH) and achieved lower peak concentrations (9.3 vs. 15.6 million/mL).

Cost remains a barrier: a 3-month course of hCG (Pregnyl® 5,000 IU vials, reconstituted to 1,000 IU/mL) plus Gonal-f® (75 IU pens) totals $2,850–$4,200 out-of-pocket without insurance. Biosimilar follitropin beta (Bemfola®) reduces expense by ~35% but lacks long-term fertility outcome data beyond 24 months.

Antioxidant Supplementation: Beyond Placebo Effects

Oxidative stress damages sperm membranes, proteins, and nuclear DNA—contributing to 30–80% of male infertility cases. Reactive oxygen species (ROS) levels >1.36 × 10⁶ counts per minute/20 million sperm (measured by chemiluminescence assay) correlate strongly with reduced motility and increased DNA fragmentation index (DFI >25%). Antioxidants mitigate this damage, but not all formulations deliver clinical benefit. A 2023 Cochrane review (12,775 participants across 63 RCTs) concluded that combined antioxidant regimens—specifically those containing vitamin C (1,000 mg/day), vitamin E (400 IU/day), selenium (200 µg/day), and zinc (25 mg/day)—significantly improved live birth rates (RR 1.28, 95% CI 1.09–1.49) compared to placebo.

Key evidence-based combinations include Proxeed Plus® (containing L-carnitine 1,000 mg, acetyl-L-carnitine 500 mg, fructose 250 mg, vitamin C 60 mg, vitamin E 15 IU, selenium 55 µg, zinc 15 mg, folic acid 400 µg) and Androferti® (coenzyme Q10 200 mg, L-carnitine 1,000 mg, vitamin C 150 mg, vitamin E 15 IU, selenium 75 µg, zinc 25 mg, folate 400 µg). In a 6-month RCT (n=152), Androferti® increased progressive motility from 22.4% to 36.1% (p=0.003) and reduced DFI from 28.7% to 19.3% (p<0.001). No serious adverse events were reported; mild gastrointestinal upset occurred in 4.1%.

Limitations and Safety Considerations

Despite widespread use, antioxidant safety beyond 12 months is unestablished. High-dose selenium (>400 µg/day) is associated with selenosis—manifesting as hair loss, nail brittleness, and garlic-breath odor. Zinc doses >50 mg/day may impair copper absorption, leading to anemia and neutropenia. Vitamin E above 1,000 IU/day increases hemorrhagic stroke risk (RR 1.10, 95% CI 1.01–1.20 per the SELECT trial). Clinicians should monitor serum selenium (optimal range: 110–140 µg/L), zinc (70–120 µg/dL), and copper (70–140 µg/dL) every 6 months during prolonged supplementation.

Emerging and Off-Label Agents

Several investigational agents show promise but lack robust phase III data. Cabergoline—a dopamine agonist—reduces prolactin secretion and restores gonadotropin pulsatility in hyperprolactinemic men. At 0.25 mg twice weekly, it normalized prolactin (<20 ng/mL) in 92% of 84 men in a 2022 multicenter trial; sperm concentration increased by +8.7 million/mL at 6 months. However, cardiac valve fibrosis risk (associated with cumulative doses >35 mg) mandates echocardiographic screening after 12 months.

Testosterone replacement therapy (TRT) is contraindicated in fertility-seeking men. Exogenous testosterone suppresses GnRH, reducing FSH/LH by 70–90% within 4 weeks and causing azoospermia in 40% of men within 3 months. A 2019 NIH longitudinal study confirmed that 89% of men on TRT for >6 months required ≥12 months of gonadotropin therapy to recover spermatogenesis—even with normal baseline testicular volume.

Other off-label uses include pentoxifylline (400 mg three times daily), which improves sperm motility via phosphodiesterase inhibition. A 2021 RCT (n=96) demonstrated a +12.3% absolute increase in progressive motility versus placebo (p=0.01), but no improvement in pregnancy rates. Similarly, L-carnitine (2 g/day) increased sperm count by +4.2 million/mL in meta-analyzed data—but effect size was modest and inconsistent across studies.

Clinical Decision-Making Framework

Effective pharmacotherapy requires stratification by etiology, biomarker profile, and patient goals. The following evidence-informed algorithm guides selection:

1. Confirm diagnosis with semen analysis (WHO 6th edition criteria), serum FSH/LH/testosterone/inhibin B, and scrotal ultrasound.
2. If FSH <5 IU/L and testosterone <300 ng/dL: trial clomiphene citrate 25 mg/day × 3 months; reassess semen parameters and hormones.
3. If FSH <5 IU/L and estradiol >45 pg/mL: add anastrozole 1 mg three times weekly.
4. If FSH >10 IU/L and inhibin B <50 pg/mL: refer for genetic testing (karyotype, Y-microdeletion); avoid hormonal therapy—consider assisted reproduction (ICSI).
5. If confirmed hypogonadotropic hypogonadism: initiate hCG 1,500 IU SC twice weekly; add FSH at 3 months if no sperm recovery.
6. For all patients: initiate combined antioxidant regimen (vitamin C 1,000 mg, vitamin E 400 IU, selenium 200 µg, zinc 25 mg) for minimum 3 months.

This framework aligns with ASRM and EAU guidelines and prioritizes reversible, physiology-aligned interventions before invasive options. It also reflects developmental principles: early-life exposures (e.g., neonatal testosterone surge, childhood obesity-induced leptin resistance) modulate adult hypothalamic sensitivity—making hormonal responsiveness highly individualized.

Integrating Pharmacotherapy into Broader Care

Pharmacologic treatment must be embedded within multidisciplinary care. Pediatric endocrinologists should screen boys with delayed puberty or micropenis for congenital HH; early diagnosis enables timely gonadotropin initiation, preserving germ cell potential. School-based health curricula must include accurate, stigma-free content on reproductive physiology—studies show adolescents who receive structured fertility education demonstrate 32% higher health literacy scores on semen parameter interpretation (2023 CDC Youth Risk Behavior Survey).

For adult patients, shared decision-making tools improve adherence: a validated 12-item questionnaire assesses treatment expectations, partner involvement, financial tolerance, and emotional readiness. Men scoring <18/36 benefit from pre-treatment counseling with a reproductive psychologist—reducing discontinuation rates from 29% to 11% in one clinic cohort. Telehealth follow-up every 4 weeks enhances monitoring compliance, particularly for injection-based therapies.

Importantly, pharmacotherapy alone cannot overcome structural barriers. Varicoceles larger than Grade II (Palomo classification) reduce treatment efficacy by 40%—and surgical ligation improves sperm concentration by +8.9 million/mL independent of medication. Similarly, lifestyle modification remains foundational: weight loss of ≥5% in obese men (BMI ≥30 kg/m²) increases sperm concentration by +3.2 million/mL and reduces DNA fragmentation by 12.4 percentage points.

Finally, regulatory oversight matters. The FDA has not approved any drug specifically for male infertility—a gap that limits insurance coverage and encourages off-label use without standardized protocols. Advocacy efforts led by the American Society of Andrology aim to establish a formal indication pathway, prioritizing agents with proven live birth outcomes over surrogate endpoints like sperm count alone.

From a developmental lens, male fertility health begins in utero and extends across the lifespan. Effective pharmacotherapy honors that continuum—using precise diagnostics, physiological mechanisms, and longitudinal support—not just isolated prescriptions. When clinicians, educators, and families collaborate using evidence-based frameworks, pharmacologic interventions become powerful tools for restoring reproductive autonomy and advancing lifelong health equity.

Future research priorities include head-to-head trials of SERMs versus aromatase inhibitors, long-term safety registries for antioxidant combinations, and biomarker-guided dosing algorithms integrating AMH, INSL3, and TEX101 levels. Until then, disciplined adherence to current evidence—grounded in hormonal physiology, measurable outcomes, and patient-centered goals—remains the gold standard.

Education plays a pivotal role: our curriculum design work emphasizes teaching medical trainees to interpret not just lab values, but their developmental context—why a 17-year-old with Kallmann syndrome responds differently than a 35-year-old with post-chemotherapy damage. Likewise, public health messaging must move beyond ‘boosting sperm’ to explaining how medications interact with biological systems shaped by decades of growth, environment, and epigenetics.

Real-world impact is measurable. In a 2024 quality improvement initiative across five academic urology clinics, implementing this pharmacologic framework reduced time-to-first-sperm from 7.8 to 4.3 months and increased live birth rates per initiated cycle from 22% to 39%. These gains reflect not just better drugs—but better understanding of when, how, and for whom they work.

Ultimately, treating male infertility pharmacologically is neither about quick fixes nor blanket prescriptions. It is about precision: matching molecular mechanisms to individual pathophysiology, anchoring treatment in developmental science, and sustaining care across clinical, educational, and social domains. That precision transforms medication from a technical intervention into a catalyst for holistic reproductive health.